Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature

Nathalie D van Burgel1, Mayke Oosterloo2, Frank P Kroon3, Alje P van Dam4

Abstract

Background: Lyme Neuroborreliosis (LNB) in a human immunodeficiency virus (HIV) positive patient is a rare co-infection and has only been reported four times in literature. No case of an HIV patient with a meningoencephalitis due to LNB in combination with HIV has been described to date.

Case presentation: A 51 year old woman previously diagnosed with HIV presented with an atypical and severe LNB. Diagnosis was made evident by several microbiological techniques. Biochemical and microbiological recovery during treatment was rapid, however after treatment the patient suffered from severe and persistent sequelae.

Conclusions: A clinician should consider LNB when being confronted with an HIV patient with focal encephalitis, without any history of Lyme disease or tick bites, in an endemic area. Rapid diagnosis and treatment is necessary in order to minimize severe sequelae.

Background

Lyme Neuroborreliosis (LNB) in a human immunodeficiency virus (HIV) positive patient is a rare co-infection and has only been reported four times [1-4]. All published cases are early presentations of Lyme disease and no report of a meningoencephalitis due to B. burgdorferi in an HIV patient has been made to date. We present a case of an HIV positive patient that presented with a severe LNB, without any previous sign of Lyme disease.

Case presentation

A 51-year-old woman, diagnosed with HIV 10 years before, presented early spring 2006 at the outpatient clinic in the west of the Netherlands. She had noticed an altered gait that was progressive since three months. Strength and sensibility were unaltered, but there was paresthesia in both legs. She also had problems unbuttoning clothing with both hands. There was no complaint of headache, photophobia or visual changes. The medical history showed an anxiety disorder, hypertension and glaucoma. At presentation, the patient had been using HAART for six years (zidovudine, lamivudine and nevirapine) in combination with antihypertensive medication and a selective serotonin reuptake inhibitor. There was no indication for antibiotic prophylaxis. She had no history of tick bites, rash, erythema migrans or other signs of early or late-stage Lyme borreliosis. However, she frequently worked in her garden in an area where B. burgdorferi is endemic. Neurological examination revealed a bipyramidal walking pattern, an intention tremor of the posture and the hands, bilateral hyperreflexia in her legs and arms, a positive Hoffman-Trömner and a bilateral Babinski. There were no meningeal signs and all cranial nerve function was intact. RR was 190/113 and temperature was normal. Routine laboratory tests showed no signs of infection; blood leucocytes level was 5,9*10^9/l. Plasma HIV RNA load was undetectable, CD4+ T lymphocyte count was 501/μl. A lumbar puncture was performed; the opening pressure was 28 cm H2O. The cerebrospinal fluid (CSF) showed a leucocytosis of 201/μl, 70% T-lymphocytes, 6% NK-cells, and 6% B-lymphocytes, glucose 2 mmol/l (serum glucose 6,2 mmol/l), protein 1,26 g/L. By isoelectric focussing oligoclonal IgG was detected intrathecally, but there was no evidence of a monoclonal B-cell population. Cytology and immunophenotyping of the...
intrathecal leucocytes were negative for haematological malignancies.

An MRI of the spine as well as brain was performed. No abnormalities were detected in the spine, but in the midline of the pontine region a hyperintense signal was seen on DUAL and FLAIR view (Figure 1-2). This lesion did not enhance under gadolinium.

CSF was examined and found PCR negative for HIV RNA, neurotropic viruses (Cytomegalovirus, Epstein Barr, Varicella zoster virus, Herpes simplex virus, JC virus), tuberculosis, toxoplasmosis, Bartonella and Treponema pallidum. CSF and serum serology was negative for T. pallidum and cryptococcal antigens. Serology for Bartonella, Babesia, Anaplasma and Ehrlichia showed no indication of an active infection. Culture was negative for cryptococcosis, tuberculosis and other common bacteria. Results for Lyme disease showed specific intrathecal IgG antibodies against B. burgdorferi in ELISA, no additional bands on blot were seen in CSF compared to serum. The intrathecal antibody index (AI) was positive (AI 19; cut off 0.3), indicating a specific production of antibodies to Borrelia in the CSF (IDEIA, Oxoid, UK). Also real-time PCR for Borrelia burgdorferi OspA conducted on the CSF was positive [5]. Serum antibodies against Borrelia were detected with the QuickELISA Borrelia C6 assay (Lyme index > 10) (Immunetics, Boston, USA), and their presence was confirmed by a positive band for p100/83, VlsE, p41(i), p39 and DbpA on the RecomBlot Borrelia IgG assay (Mikrogen, Martinsreid, Germany). A serum from three years preceding this clinical presentation tested completely negative for antibodies against B. burgdorferi.

The diagnosis of a Lyme meningoencephalitis was made. The patient was treated intravenously with ceftriaxone 2 g/day for 1 month according to the EUCALB guideline. During the first week of treatment her clinical condition worsened. She was no longer able to walk independently and was forced to use a wheelchair. The cerebral MRI however showed decline of the hyperintense region at the end of intravenous treatment. An MRI performed one month later showed no abnormalities at all (Figure 3). In addition, posttreatment CSF showed a reduction in pleocytosis (7/μl), an absence of intrathecal specific antibodies against Borrelia and the real-time PCR for OspA on the CSF was negative. After a year of regular check up the patients’ physical examination showed paraparesis of the right m. iliopsoas grade 4, right hamstrings grade 3, right footlifters degree 4 and hyperreflexia of both legs with Babinski signs. The bipyramidal walking pattern was still present. The patient was able to stand alone and walk with a...
cane. No further clinical improvement was detected at regular check up for four years.

Discussion

We describe a case of a patient with an HIV infection and severe neurology and MRI lesions due to a *B. burgdorferi* central nervous system (CNS) infection. After treatment with ceftriaxone the laboratory parameters of infection disappeared along with the abnormalities on MRI, however the patient persistently suffered from severe verifiable sequelae.

Diagnosing Lyme disease using serology in patients with HIV is complicated due to reduced positive predictive value of serology in HIV patients [6]. Also, false positive serologic findings are described in patients with neurological infections with other spirochetes such as *Treponema pallidum* [7]. Present patients’ clinical presentation was compatible with a localised cerebral infection with *B. burgdorferi*, confirmed by the positive serology, intrathecal specific anti- *Borrelia* antibody production and a positive real-time PCR for *B. burgdorferi* OspA on the CSF. The sensitivity of the OspA real-time PCR on CSF is only about 50% but the specificity is very high >99% [5]. In HIV positive patients where diagnosis of LNB by an indirect method such as serology is already compromised, a method where the microorganism is detected directly is of great value.

Little is known about the course of LNB in HIV patients. Animal models have shown that CD4 + T-cells facilitate clearance of *B. burgdorferi* [8]. In recent studies the importance of CXCL13 in B-cell recruitment in patients with LNB has been suggested [9]. In HIV infection the levels of CXCL13 in serum are elevated and the receptor CXCR5 on B-cells is down regulated causing impaired trafficking of B-cells [10]. Inadequate humoral response could lead to accelerated progression of LNB. In animal experiments immunodeficiency leads to higher spirochete burdens and higher infectivity of *B. burgdorferi* [11]. In contrast, reports from a study where Lyme borreliosis patients were treated with immunosuppressive agents, no significant effect on clinical course and response to treatment was observed [12]. *T. pallidum* is a spirochete and more is known about disease course in syphilis HIV co-infection. Disease course is altered in *T. pallidum* and HIV co-infections; there is a higher rate of asymptomatic infection, a faster progression to secondary disease which is often more aggressive with a significant predisposition for the development of neurological complaints. However, after treatment HIV positive patients recover as well as the HIV negative population [13,14]. In co-infections of HIV and *Leptospira* species, a more fulminant disease course has also been suggested [15]. For LB and HIV co-infections no such synergistic complications have been described in patients to date.

Despite the high incidence of HIV, co-infection with *B. burgdorferi* is not reported very often [1-4]. The low incidence of HIV LNB co-infections can not be easily explained. In HIV infection antibiotic prophylaxis is sometimes prescribed but none of the reported cases of HIV patients with LNB used antibiotic prophylaxis. Prophylaxis usually consists of cotrimoxazole, which is ineffective against *B. burgdorferi* which renders a positive effect of antibiotic prophylaxis on the development of Lyme disease unlikely [16]. There is no data about antibiotic activity for anti-retroviral mediation but an association seems unlikely because three of the five described patients were using anti-retroviral medication. All reported LNB HIV patients’ results have been summarized in table 1 and table 2. Case 1 had an EM and presented with a rather classical course of a bilateral facial palsy shortly after noticing the EM, rapidly improving on IV ceftriaxone treatment. HIV serology was found positive during workup for the cause of his bilateral facial palsy, CD4+ count was decreased at that time. Case 2 had a low CD4+ count with progression to neuroborreliosis, despite treatment for his recent early LB. Serology in CSF and serum was clearly positive for an early LNB. After IV treatment with ceftriaxone he recovered completely. Case 3 had a very low CD4+ count and was the only case that met the criteria for AIDS. He primarily showed a slow seroconversion although this was only determined by indirect immunofluorescence and not by ELISA or Western Blot. Four months after presentation with a painful radiculitis he had low detectable Ig titers against *Borrelia* by ELISA and Western Blot. He recovered completely. Case 4 had a moderately low CD4+ count and had a classical course of EM, followed by malaise and a facial palsy with signs of early LNB in serology of CSF and serum. He responded well to treatment with IV cefotaxime. Case 5 the present case had a moderately low CD4+ T-lymphocyte count and had rapid progression to a meningoencephalitis. This is the only case described to date of an HIV patient with a Lyme meningoencephalitis. The course of disease was rapid and atypical with a primary presentation of altered gait due to Lyme meningoencephalitis, which is an uncommon presentation of neuroborreliosis, found in only 3-5% of patients with LNB [17]. Diagnosis was made obvious due to positive PCR combined with positive IgG serology in CSF and serum. After treatment microbiological response was rapid. AI returned negative after two months, which is a rapid decline but not uncommon in literature [18]. Despite this rapid improvement biochemically and microbiologically severe sequelae remained. Posttreatment sequelae are rare. Patients with posttreatment sequelae have complaints of fatigue, cognitive impairment and paresthesia but sequelae are rarely as severe after a relatively short...
duration of illness as in this case [17,19,20]. Although this patient had complaints for only three months, it is likely that earlier recognition and treatment of LNB in this patient would have led to less neurological damage and therefore to better recovery.

Conclusions
A clinician should consider LNB as a rare possible cause of focal encephalomyelitis in an HIV patient, without any history of Lyme disease or tick bites in an area endemic for Lyme disease. Diagnosis of LNB can be compromised in HIV co-infected patients, however when applying optimal serological and molecular diagnostic techniques confirming LNB is imminent. This report raises the possibility that LNB might take a more severe course in immunocompromised patients, such as those with HIV infection.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Table 1 Clinical data from all patients with LNB and HIV reported in literature.

| Case no.* | Anti-retroviral | Antibiotic prophylaxis | Skin manifestations | Presentation | Treatment | Clinical recovery |
|-----------|----------------|------------------------|---------------------|--------------|-----------|-------------------|
| 1         | none           | none                   | Annular erythematous lesion | Several weeks later: fever, bilateral facial palsy | IV ceftriaxone 2 g/day 14 days | After treatment vast improvement 2 months, complete recovery |
| 2         | Zidovudine    | none reported          | Erythema            | Headache, painful limbs, weight loss, pneumonia | Primarily: PO Azithromycin 1 day 500 mg, 4 days 250 mg | Progression to neuroborreliosis |
|           |                | Saquinavir             |                     |              |           |                   |
|           |                | Zalcitabine            |                     |              |           |                   |
| 3         | Zidovudine    | none reported          | Erythematous lesion  | 4 weeks later: radiculitis | IV ceftriaxone 2 g/day 15 days | Complete recovery |
|           |                | Didanosine             |                     |              |           |                   |
| 4         | none           | none reported          | Multiple            | Fever, chills, arthralgias | IV cefotaxime 2 g TID 21 days | Improved rapidly |
|           | Zalcitabine   | reported               | Maculopapular lesions | 2 weeks later left facial palsy | After treatment mild facial palsy | 6 months, slight hypokinesia face |
|           | Zalcitabine   | reported               | Maculopapular lesions | 2 weeks later left facial palsy | After treatment mild facial palsy | 6 months, slight hypokinesia face |
| 5         | Zidovudine    | none                   | None                | Altered gait for months | IV ceftriaxone 2 g/day 1 month | After treatment severe sequelae |
|           |                | Lamivudine             |                     |              |           |                   |
|           |                | Nevirapine             |                     |              |           |                   |

*Case 1[1], 2[2], 3[3], 4[4], 5 this report.

Table 2 Laboratory data from all patients with LNB and HIV reported in literature.

| Case no.* | Age | Sex | Yrs HIV | Blood CD4+ count (/μl)* | CSF cell count (/μl)* | Protein (g/l) | CT/MRI | Serum Serology | CSF Serology |
|-----------|-----|-----|---------|-------------------------|----------------------|--------------|--------|----------------|--------------|
| 1         | 39  | M   | 0       | 386                     | 30                   | 1.02         | nd     | IgG + ELISA/WB | IgG + ELISA/WB |
| 2         | 39  | M   | 1       | 250                     | 496                  | 3.62         | nd     | IgM +/IgG - ELISA IgG + (month 4) WB IgG + IF Negative >4 months | IgG + ELISA IgG + (month 4) WB IgG + |
| 3         | 50  | M   | 10      | 70                      | 'aseptic meningitis' | nd           |        |                |              |
| 4         | 46  | M   | 16      | 426                     | 416                  | 3.02         | normal | IgM +/IgG + ELISA/WB | IgM +/IgG + ELISA/WB |
| 5         | 51  | F   | 11      | 501                     | 200                  | 1.26         | abnormal | IgM -/IgG + ELISA/WB | IgM -/IgG + ELISA/WB |

*Case 1[1], 2[2], 3[3], 4[4], 5 this report. Serology was performed by ELISA, Western blot (WB), or indirect immunofluorescence (IF). (nd = not done)* normal range peripheral blood; case 1: 580-1570/μl, case 3: 600-1000/μl, case 5: 560-1490/μl
Acknowledgements

The authors would like to thank Gerrit van der Luijt for preparing the CT and MRI pictures for publication and Pulak Goswami for proofreading the manuscript.

Author details

1Department of Medical Microbiology, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands. 2Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands. 3Department of Infectious Diseases, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden, the Netherlands. 4Onze Lieve Vrouwen Gasthuis, Department of Clinical Microbiology, OLVG Hospital, Amsterdam, the Netherlands.

Authors’ contributions

Clinical work-up and literature search were performed by NDvB, MO, FPK, APvD. All authors made critical contributions to the paper and approved the final manuscript.

Competing interests

Financial disclosure related to research covered in this article: none for all authors.

Received: 16 June 2010 Accepted: 30 November 2010 Published: 30 November 2010

References

1. Garcia-Monco JC, Frey HM, Villar BF, Golightly MG, Benach JL: Lyme disease concurrent with human immunodeficiency virus infection. Am J Med 1989, 87:525-528.
2. Dudge G, Opravil M, Luthy R, Weber R: [Meningitis after acute Borrelia burgdorferi infection in HIV infection]. Dtsch Med Wochenschr 1997, 122:1178-1180.
3. Cordoliani F, Vignon-Pennamen MD, Assous MV, Vabres P, Dronne P, Rybojad M, et al: Atypical Lyme borreliosis in an HIV-infected man. Br J Dermatol 1997, 137:437-439.
4. Cerny R, Machala L, Bojar M, Rozsypal H, Picha D: Neuroborreliosis in an HIV-1 positive patient. Infection 2006, 34:100-102.
5. Geoerkens J, Templeton KE, Claas EC, van Dam AP: Evaluation of an internally controlled real-time PCR targeting the ospA gene for detection of Borrelia burgdorferi sensu lato DNA in cerebrospinal fluid. Clin Microbiol Infect 2006, 12:894-900.
6. Raoult D, Vugia DJ, Nelson N, Baranton G, Harder EM, Taubenberger JK, et al: Cross-reaction with Borrelia burgdorferi antigen of sera from patients with human immunodeficiency virus infection, syphilis, and leptospirosis. J Clin Microbiol 1989, 27:2152-2155.
7. Blatz R, Kuhn HJ, Hermann W, Ryitter M, Rodloff AC: [Neurosyphilis and neuroborreliosis. Retrospective evaluation of 22 cases]. Zentralbl Neurochir 2005, 66:724-732.
8. Buchknenstedt LK, Kang I, Chang C, Persing DH, Huydaya D, Barthold SW: CD4+ T helper 1 cells facilitate regression of murine Lyme carditis. Infect Immun 2001, 69:5264-5269.
9. Senel M, Ruprecht TA, Tumani H, Pfister HW, Ludolph AC, Bretschneider J: The chemokine CXCL13 in acute neuroborreliosis. J Neural Neurosurg Psychiatry 2010, 81:929-933.
10. Widney DP, Bees EC, Boscardin WJ, Kitchin SG, Alcantar JM, Smith JB, et al: Serum levels of the homeostatic C3 chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res 2005, 25:702-706.
11. Barthold SW, Sidman CL, Smith AL: Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am J Trop Med Hyg 1992, 47:655-659.
12. Furst B, Glaz M, Kell H, Mullerger R: The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients. Clin Exp Dermatol 2006, 31:509-514.
13. Karp G, Slaiby F, Jakobowitz A, Reisenberg K: Syphilis and HIV coinfection. Eur J Intern Med 2009, 20:9-13.
14. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Augenbraun MH, Chiu M, et al: A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997, 337:307-314.
15. Jones S, Kim T: Fulminant leptospirosis in a patient with human immunodeficiency virus infection: case report and review of the literature. Clin Infect Dis 2001, 33:E31-E33.
16. Baradaran-Dilmaghani R, Stanet G: In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 1996, 24:60-63.
17. Hansen K, Lebecch AM: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 1992, 115(Pt 2):399-423.
18. Lipstad U, Skarpaas, T, Mygland A: Clinical usefulness of intrathecal antibody testing in acute Lyme neuroborreliosis. Eur J Neurol 2007, 14:873-876.
19. Shadick NA, Phillips CB, Logigian EL, Steege AC, Kaplan RF, Berardi VP, et al: The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med 1994, 121:560-567.
20. Logigian EL, Kaplan RF, Steege AC: Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990, 323:1438-1444.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2377/10/117/prepub